GLP-1: The People Who Shouldn’t Take It

Affiliate disclosure: This article contains affiliate links, and allcheminfo.com may earn a commission if you use them, at no extra cost to you. This article is informational and is not medical advice — whether a GLP-1 drug is safe for you is a decision for a qualified clinician who knows your full history.

GLP-1 drugs — semaglutide, tirzepatide and the rest — are now used by a large share of adults, and for good reason: they treat type 2 diabetes and obesity effectively. But “effective for many” is not the same as “safe for everyone.” Some people genuinely should not take these medications at all. Others can, but only with extra caution, closer monitoring, or a specialist’s input first. Screening for exactly these situations is something any responsible prescriber does before writing the first prescription. This article is an honest, organized guide to the GLP-1 contraindications and cautions — who should not take these drugs, who needs a careful conversation first, and why disclosing your full medical history matters.

The Absolute Contraindications

A handful of situations are firm “no” answers — not cautions to weigh, but reasons a GLP-1 drug should not be used.

The first and most important is a personal or family history of medullary thyroid carcinoma, a specific type of thyroid cancer, or of Multiple Endocrine Neoplasia syndrome type 2 (MEN2), a genetic condition that carries a high risk of that cancer. This is the basis of the boxed warning — the FDA’s most serious warning — that semaglutide, tirzepatide and the other drugs in this class carry. In rodent studies, these drugs caused thyroid C-cell tumors; whether that risk extends to humans is not settled, but for anyone with that personal or family history, the drugs are contraindicated. This is precisely why a proper intake evaluation asks about thyroid cancer history — and if a provider prescribes a GLP-1 drug without ever asking, that is a genuine warning sign about the quality of that provider.

The second is a known serious allergic reaction to the specific drug or any of its ingredients. A history of a severe hypersensitivity reaction — not ordinary, manageable side effects, but a true allergic reaction — to semaglutide, tirzepatide or a component means that drug should not be used again.

These are not situations where benefits can be weighed against risks. They are reasons the answer is simply no.

Pregnancy, Breastfeeding, and Birth Control

For anyone who is pregnant, may become pregnant, or is breastfeeding, GLP-1 drugs require particular care — and this is one of the most important, and most misunderstood, areas.

GLP-1 drugs are not recommended during pregnancy. There is not enough human safety data to know whether they can harm a developing baby, and animal studies have raised concerns about fetal harm. On top of that, deliberate weight loss is not advised during pregnancy in the first place. If a person becomes pregnant while taking a GLP-1 drug, the standard advice is to stop and contact their clinician promptly.

Because of this, anyone planning a pregnancy is generally advised to stop the drug well in advance — long enough for it to clear the body. The exact timing depends on the drug: regulatory guidance suggests stopping semaglutide roughly two months before trying to conceive, and tirzepatide roughly one month before, reflecting how long each takes to clear. The precise timing is a conversation to have with a clinician.

Breastfeeding is a similar picture: there is little data on whether these drugs pass into breast milk or how they might affect a nursing infant, and most clinicians advise against using them while breastfeeding until more is known.

There is also a contraception point that is specific to tirzepatide — and easy to miss. Tirzepatide can reduce the effectiveness of oral contraceptive pills, because slowing stomach emptying affects how the pill is absorbed. For that reason, women using the pill are advised, when taking tirzepatide, either to switch to a non-oral method of contraception, or to add a barrier method such as condoms — for four weeks after starting tirzepatide, and for four weeks after each dose increase. Semaglutide does not appear to carry this interaction, so this backup-contraception advice applies specifically to tirzepatide. Either way, because GLP-1 drugs are not for use in pregnancy, reliable contraception while taking them matters.

Conditions That Call for Caution and a Closer Look

Beyond the absolute bars, a number of conditions do not automatically rule out a GLP-1 drug but do call for careful clinical judgment, closer monitoring, or a specialist’s review before starting.

A history of pancreatitis is the clearest example. Pancreatitis is a recognized, if uncommon, risk of GLP-1 drugs, and someone who has had it before should generally only start treatment after a specialist has reviewed their case and judged it reasonable.

Severe gastrointestinal motility disorders, gastroparesis in particular, are another. GLP-1 drugs work partly by slowing stomach emptying — and in someone whose stomach already empties too slowly, that effect can worsen symptoms and, in serious cases, raise the risk of complications. Significant gut motility disease is generally a reason for caution or avoidance.

A history of gallbladder disease warrants a closer look too, since GLP-1 drugs and the rapid weight loss they produce both raise the risk of gallstones. Significant kidney disease calls for caution, mainly because dehydration from the drugs’ gastrointestinal side effects can strain the kidneys. And for people with diabetes who have a history of diabetic retinopathy, rapid improvement in blood sugar can temporarily worsen that eye condition, so it may need closer monitoring.

Mental health history belongs here as well. The labels for the weight-management drugs advise monitoring for depression or worsening mood, and although regulatory reviews have not found that GLP-1 drugs cause suicidal thoughts, anyone with a significant history of depression or suicidal ideation should make sure their prescriber knows, so that mood can be watched during treatment.

None of these is automatically disqualifying. The point is that they change the conversation — and they are reasons a prescriber needs an honest, complete picture of your history.

A History of an Eating Disorder

One screening area deserves its own attention, because it is both genuinely important and frequently overlooked: a history of an eating disorder.

GLP-1 drugs work by suppressing appetite and producing weight loss — and for someone with a history of disordered eating, those exact effects can be harmful. They can reactivate restrictive patterns, be misused as a way to eat as little as possible, and mask the signs of an eating disorder so that it goes unnoticed for longer. A 2026 joint advisory from several major obesity and nutrition organizations was direct about it: a restrictive eating disorder, such as anorexia, is treated as a general contraindication to GLP-1 use, and anyone with any history of an eating disorder who is considering these drugs should be evaluated by both an obesity medicine specialist and an eating disorders specialist before starting.

The picture is not identical across all eating disorders — research into GLP-1 drugs and binge eating disorder is ongoing and more mixed — but the consistent message from clinicians is caution, specialist involvement and close monitoring rather than a routine prescription. The practical difficulty is that screening for this is not yet standard everywhere, and many providers do not ask. If you have a current or past eating disorder, or a difficult relationship with eating, it is essential to raise this with a clinician before starting a GLP-1 drug — and a good provider will want to know.

When a GLP-1 Drug Is the Wrong Tool

Separate from contraindications, there are situations where a GLP-1 drug is simply not the right medication.

The clearest is type 1 diabetes. GLP-1 drugs are approved for type 2 diabetes and for weight management — not for type 1 diabetes, and they are not a substitute for insulin. A person with type 1 diabetes who reduced or stopped insulin in favor of a GLP-1 drug would be at risk of diabetic ketoacidosis, a dangerous condition. Type 1 diabetes was not the population these drugs were designed or tested for.

The other situation is subtler but worth stating plainly: GLP-1 drugs are not casual cosmetic products. They are powerful medications with real risks, intended for people with a genuine medical indication — type 2 diabetes, or obesity, or overweight with a weight-related health condition. Using them to lose a few cosmetic pounds without such an indication means taking on the risks of a serious medication without the medical rationale that justifies them. A legitimate prescriber screens for a real indication; the absence of that screening is, again, a warning sign.

Drug Interactions to Know

A few interactions are worth knowing, though most are manageable rather than disqualifying.

The most important involves other diabetes medications. On their own, GLP-1 drugs carry a low risk of dangerously low blood sugar — but combined with insulin or with sulfonylurea diabetes drugs, that risk rises, and the doses of those other medications often need to be reduced. Anyone taking insulin or a sulfonylurea should have this managed deliberately by their prescriber, not left to chance.

Because GLP-1 drugs slow stomach emptying, they can also affect how quickly oral medications are absorbed. For most drugs this is not a practical problem, but it is the mechanism behind the tirzepatide–oral-contraceptive interaction described earlier, and it is worth mentioning to a prescriber if you take an oral medication where precise, consistent absorption matters.

Finally, a practical caution that is not strictly an interaction but belongs on any list like this: because of the delayed stomach emptying, GLP-1 drugs matter for surgery and anesthesia. Anyone scheduled for a procedure should tell their surgeon and anesthesiologist that they take one — a point we cover, alongside the drugs’ other effects, in our guide to GLP-1 side effects beyond the gut.

Frequently Asked Questions

Who should not take GLP-1 drugs?

Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, or a serious allergy to the drug, should not take them — these are absolute contraindications. They are also not recommended during pregnancy or breastfeeding, and they are not a treatment for type 1 diabetes. A history of an eating disorder calls for specialist evaluation first, and a restrictive eating disorder is generally a contraindication. Several other conditions require caution and a clinician’s review rather than ruling treatment out entirely.

Can I take a GLP-1 drug if I have had pancreatitis?

It is not automatically ruled out, but it requires care. Pancreatitis is a recognized risk of these drugs, so someone with a prior episode should generally only start treatment after a specialist has reviewed their case and judged it reasonable.

Do GLP-1 drugs affect birth control?

Tirzepatide can reduce the effectiveness of oral contraceptive pills by slowing their absorption. Women on the pill who take tirzepatide are advised to switch to a non-oral method or add a barrier method for four weeks after starting and after each dose increase. Semaglutide does not appear to carry this interaction.

Can I take a GLP-1 drug while pregnant or trying to conceive?

No — GLP-1 drugs are not recommended in pregnancy, as there is not enough safety data and deliberate weight loss is not advised during pregnancy anyway. Anyone planning a pregnancy is generally advised to stop in advance — roughly two months ahead for semaglutide and one month for tirzepatide — with the exact timing decided by a clinician.

Why does my provider need my full medical history?

Because several conditions — thyroid cancer history, pancreatitis, severe gut disorders, gallbladder disease, mental health history and more — change whether and how a GLP-1 drug can be used safely. A provider who prescribes without taking that history is not screening properly, which is itself a warning sign about the provider.

The Bottom Line

GLP-1 drugs are effective and, for most of the people who take them, reasonably safe. But they are real medications with real contraindications. A few situations are firm bars: a personal or family history of medullary thyroid cancer or MEN2 syndrome, a serious allergy to the drug, and pregnancy. A history of an eating disorder calls for specialist evaluation before any GLP-1 drug, and a restrictive eating disorder is generally a contraindication in itself. Others — a history of pancreatitis, severe gut motility disorders, gallbladder or significant kidney disease, a mental health history — do not rule treatment out but call for caution, monitoring, and sometimes a specialist’s review. And type 1 diabetes, or the absence of any genuine medical indication, means a GLP-1 drug is the wrong tool.

The single thread running through all of it is screening. Every item on this list is something a competent prescriber asks about before starting treatment — which is the strongest practical argument for getting these drugs through a legitimate, properly evaluating provider, and for telling that provider everything, even the parts that seem irrelevant. The contraindications exist to keep treatment safe. They only do their job if someone is actually checking.

This article is general information, not medical advice. Contraindication and regulatory guidance reflects the situation as of May 2026 and can change; whether a GLP-1 drug is safe for you must be decided with a qualified clinician who knows your full history.